VN

VolitionRX LtdNYSE-MKT VNRX Stock Report

Last reporting period 30 Jun, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

0.056

Micro

Exchange

XASE - Nyse MKT LLC

VNRX Stock Analysis

VN

Uncovered

VolitionRX Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-59/100

Low score

Market cap $B

0.056

Dividend yield

Shares outstanding

63.097 B

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 104 full-time employees. The company went IPO on 2015-02-06. The Company’s tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids. Its Nucleosomics technology uses chromosomal structures called nucleosomes as biomarkers in cancer and other diseases. Its key pillars include Nu.Q , Nu.Q NETs, Nu.Q Capture, Nu.Q Discover and Nu.Q Vet. Its Nu.Q family of tests acts as an early warning system by monitoring treatment response, disease progression and remission. Its Nu.Q tests use epigenetic information from tumor cells nucleosomes that helps physicians select the treatment for each patient, monitor their response and disease progression.

View Section: Eyestock Rating